AR051195A1 - Piridinas como inhibidores de plk - Google Patents
Piridinas como inhibidores de plkInfo
- Publication number
- AR051195A1 AR051195A1 ARP050103502A ARP050103502A AR051195A1 AR 051195 A1 AR051195 A1 AR 051195A1 AR P050103502 A ARP050103502 A AR P050103502A AR P050103502 A ARP050103502 A AR P050103502A AR 051195 A1 AR051195 A1 AR 051195A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- nr4c
- nr8c
- halogen
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Compuesto de la formula general (1), en los que significan: W es N o C-R2; X es -NR1a, O o S; Y es CH o N; Z es hidrogeno, halogeno, -NO2, alquiloC1-3-, alqueniloC2-3-, alquiniloC2-3-, halogen-alquiloC1-3-, -COH, -C(=O)-alquiloC1- 3, -C(=O)-alqueniloC2-3, -C(=O)-alquiniloC2-3, -C(=O)alquilC1-3-halogeno y pseudohalogeno; A es seleccionado de las formulas (2), (3) o (4); Q1 es compuestos arilo mono- o bicíclicos; B1, B2, B3 y B4 cada uno, de modo independiente entre sí, C-R9Rh, N-Ri, O o S; R1 y R1a cada uno, de modo independiente entre sí, hidrogeno o metilo; R2 es un radical seleccionado del grupo compuesto por hidrogeno, halogeno, -OR4, -C(=O)R4, -C(=O)NR4R5, -NR4R5, -NR4C(=O)R5, -NR4SO2R5, -N=CR4R5, -C=NRi, -SR4, - SOR4, -SO2R4, -SO2NR4R5 y pseudohalogeno, o un radical eventualmente mono- o polisustituido seleccionado del grupo compuesto por alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, arilo, heterociclilo y heteroarilo, en donde el o los sustituyen pueden ser iguales o diferentes y están seleccionados del grupo compuesto por halogeno, -NO2, -OR4, -C(=O)R4, -C(=O)OR4, -C(=O)NR4R5, -NR4R5, -NR4C(=O)R5, -NR4C(=O)OR5, -NR4C(=O)NR5R6, -NR4SO2R5, -N=CR4R5, -SR4, -SOR4, -SO2R4, -SO2NR4R5, - NR4SO2NR5R6, -OSO2NR5R6 y pseudohalogeno; Ra, Rb, Rc, Rd, Re, Rf, Rg y Rh cada uno, de modo independiente entre sí, un radical seleccionado del grupo compuesto por hidrogeno, halogeno, =O, -NO2, -OR4, -C(=O)R4, -C(=O)OR4, -C(=O)NR4R5, -NR4R5, - NR4C(=O)R5, -NR4C(=O)OR5, -NR4C(=O)NR5R6, -NR4SO2R5, -N=CR4R5, -C=NRi, -SR4, -SOR4, -SO2R4, -SO2NR4R5, -NR4SO2NR5R6, -OSO2NR5R6 y pseudohalogeno; o un radical eventualmente mono- o polisustituido seleccionado del grupo compuesto por alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, arilo, heterociclilo y heteroarilo, en donde el o los sustituyen pueden ser iguales o diferentes y están seleccionados del grupo compuesto por halogeno, R8, -NO2, -OR4, -C(=O)R4, -C(=O)OR4, - C(=O)NR4R5, -NR4R5, -NR4C(=O)R5, -NR4C(=O)OR5, -NR4C(=O)NR5R6, -NR4SO2R5, -N=CR4R5, -SR4, -SOR4, -SO2R4, -SO2NR4R5, -NR4SO2NR5R6, -OSO2NR5R6 y pseudohalogeno; o eventualmente Rg y Rh que se hallan en los mismos o en átomos de C adyacentes pueden estar unidos en cualquier combinacion con un puente de alquilo comun de 3-5 miembros saturado o parcialmente insaturado, que eventualmente puede contener uno a dos heteroátomos; Rf un radical seleccionado del grupo compuesto por hidrogeno, =O, -OR4, -C(=O)R4, -C(=O)OR4, -C(=O)NR4R5, -NR4R5, -NR4C(=O)R5, -NR4C(=O)OR5, -NR4C(=O)NR5R6, -NR4SO2R5, -N=CR4R5, -SR4, -SOR4, -SO2R4, -SO2NR4R5, -NR4SO2NR5R6, -OSO2NR5R6 o un radical eventualmente mono- o polisustituido seleccionado del grupo compuesto por alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, arilo, heterociclilo y heteroarilo, en donde el o los sustituyen pueden ser iguales o diferentes y están seleccionados del grupo compuesto por halogeno, R8, -NO2, -OR4, -C(=O)R4, - C(=O)OR4, -C(=O)NR4R5, -NR4R5, -NR4C(=O)R5, -NR4C(=O)OR5, -NR4C(=O)NR5R6, -NR4SO2R5, -N=CR4R5, -SR4, -SOR4, -SO2R4, -SO2NR4R5, -NR4SO2NR5R6, -OSO2NR5R6 y pseudohalogeno; o eventualmente los Ri que se hallan en átomos de N adyacentes pueden estar unidos entre sí o Ri con Rg o Rh que se hallan en átomos de C adyacentes en cualquier combinacion con un puente de alquilo comun de 3-5 miembros saturado o parcialmente insaturado, que puede contener uno a dos heteroátomos; R3 está seleccionado de las formulas (5)-(11); R4, R5 y R6 cada uno, de modo independiente entre sí, hidrogeno o un radical seleccionado del grupo compuesto por alquilo C1-5, alquenilo C2-5, alquinilo C2-5, cicloalquilo C3-10, arilo, heterociclilo y heteroarilo eventualmente mono- o polisustituido, en donde el o los sustituyentes pueden ser iguales o diferentes y están seleccionados del grupo compuesto por cicloalquilo C3-10, arilo, heterociclilo, heteroarilo, halogeno, -NO2, -OR8, -C(=O)R8, -C(=O)OR8, - C(=O)NR8R9, -NR8R9, -NR8C(=O)R9, -NR8C(=O)OR9, -NR8C(=O)NR9R10, -NR8C(=O)ONR9R10, -NR8SO2R9, -N=CR8R9, -SR8, -SOR8, -SO2R8, -SO2NR8R9, -NR8SO2NR9R10, -OSO2NR8R9 y pseudohalogeno; L es un enlace o un radical seleccionado del grupo compuesto por alquilo C1-16, alquenilo C2-16, alquinilo C2-16, cicloalquilo C3-10, arilo, heterociclilo y heteroarilo eventualmente mono- o polisustituido, en donde el o los sustituyentes pueden ser iguales o diferentes y están seleccionados del grupo compuesto por halogeno, -NO2, -NR2, -OR8, -C(=O)R8, -C(=O)OR8, -C(=O)NR8R9, -NR8R9, -NR8C(=O)R9, -NR8C(=O)OR9, -NR8C(=O)NR9R10, -NR8C(=O)ONR9R10, -NR8SO2R9, -N=CR8R9, -SR8, -SOR8, -SO2R8, -SO2NR8R9, -NR8SO2NR9R10, -OSO2NR8R9 y pseudohalogeno; Q2 y Q3 cada uno, de modo independiente entre sí, un enlace o un radical seleccionado del grupo compuesto eventualmente por alquilo C1-16, alquenilo C2-16, alquinilo C1-16, cicloalquilo C3-10, arilo, heterociclilo y heteroarilo, en donde el o los sustituyentes pueden ser iguales o diferentes y están seleccionados del grupo compuesto por halogeno, -NO2, -OR8 -C(=O)R8 -C(=O)OR8 -C(=O)NR8R9-, NR8R9, -NR8C(=O)R9, -NR8C(=O)OR9, -NR8C(=O)NR8R10, -NR8C(=O)ONR9R10, -NR8SO2R9, -N=CR8R9, -SR8, -SOR8, -SO2R8, - SO2NR8R9, -NR8SO2NR9R10, -OSO2NR8R9 y pseudohalogeno; R7 es hidrogeno o un radical seleccionado del grupo compuesto por alquilo C1-16, alquenilo C2-16, alquinilo C2-16, cicloalquilo C3-10, arilo, heterociclilo y heteroarilo eventualmente mono- o polisustituido, en donde el o los sustituyentes pueden ser iguales o diferentes y están seleccionados del grupo compuesto por halogeno-, NO2, -OR8, -C(=O)R8, -C(=O)OR8, -C(=O)NR8R9, -NR8R9, -NR8COR9, -NR8C(=O)OR9, -NR8C(=O)NR9R10, -NR8C(=O)ONR9R10, - NR8SO2R9, -N=CR8R9, -SR8, -SOR8, -SO2R8, -SO2NR8R9, -NR8SO2NR9R10, -OSO2NR8R9 y pseudohalogeno; R8, R9 y R10 cada uno, de modo independiente entre sí, hidrogeno o un radical seleccionado del grupo compuesto por alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10, arilo, heterociclilo y heteroarilo eventualmente sustituido, en donde el o los sustituyentes pueden ser iguales o diferentes y están seleccionados del grupo compuesto por halogeno, metilo, etilo, amino, metilamino, dimetilamino, -OH y pseudohalogeno; eventualmente en forma de sus tautomeros, sus racematos, sus enantiomeros, sus diastereoisomeros y sus mezclas, así como eventualmente de sus sales por adicion de ácidos farmacologicamente inocuas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04019775 | 2004-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051195A1 true AR051195A1 (es) | 2006-12-27 |
Family
ID=34926239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103502A AR051195A1 (es) | 2004-08-20 | 2005-08-22 | Piridinas como inhibidores de plk |
Country Status (20)
Country | Link |
---|---|
US (4) | US7521457B2 (es) |
EP (1) | EP1781640B1 (es) |
JP (1) | JP5060294B2 (es) |
KR (1) | KR101277506B1 (es) |
CN (1) | CN101044137A (es) |
AR (1) | AR051195A1 (es) |
AU (1) | AU2005276500B2 (es) |
BR (1) | BRPI0514371A (es) |
CA (1) | CA2573371C (es) |
DK (1) | DK1781640T3 (es) |
ES (1) | ES2532611T3 (es) |
HU (1) | HUE025285T2 (es) |
IL (1) | IL181421A (es) |
MX (1) | MX2007002055A (es) |
NZ (1) | NZ553632A (es) |
PL (1) | PL1781640T3 (es) |
RU (1) | RU2404979C2 (es) |
TW (1) | TWI421248B (es) |
WO (1) | WO2006021544A1 (es) |
ZA (1) | ZA200700084B (es) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
TW200804364A (en) * | 2006-02-22 | 2008-01-16 | Boehringer Ingelheim Int | New compounds |
EP2007754A1 (en) * | 2006-04-10 | 2008-12-31 | Boehringer Ingelheim International GmbH | 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer |
US8623887B2 (en) * | 2006-05-15 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Compounds |
DE102006039003A1 (de) | 2006-08-19 | 2008-02-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Verbindungen |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20100120717A1 (en) * | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
CA2669111C (en) | 2006-10-23 | 2016-04-12 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
ES2593486T3 (es) * | 2007-04-18 | 2016-12-09 | Pfizer Products Inc. | Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo |
JP5204838B2 (ja) * | 2007-05-16 | 2013-06-05 | イーライ リリー アンド カンパニー | トリアゾリルアミノピリミジン化合物 |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
AR067413A1 (es) | 2007-07-05 | 2009-10-07 | Genentech Inc | Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer |
JP2010533700A (ja) * | 2007-07-16 | 2010-10-28 | アストラゼネカ アクチボラグ | ピリミジン誘導体 |
EP2025675A1 (de) | 2007-08-14 | 2009-02-18 | Boehringer Ingelheim International GmbH | Arylsulfonamide mit analgetischer Wirkung |
WO2009021944A1 (de) | 2007-08-14 | 2009-02-19 | Boehringer Ingelheim International Gmbh | Neue verbindungen |
US8278313B2 (en) | 2008-03-11 | 2012-10-02 | Abbott Laboratories | Macrocyclic spiro pyrimidine derivatives |
EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
US8436005B2 (en) | 2008-04-03 | 2013-05-07 | Abbott Laboratories | Macrocyclic pyrimidine derivatives |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
CA2735560A1 (en) * | 2008-08-12 | 2010-02-18 | Boehringer Ingelheim International Gmbh | Process for preparing cycloalkyl-substituted piperazine compounds |
EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
TWI491605B (zh) | 2008-11-24 | 2015-07-11 | Boehringer Ingelheim Int | 新穎化合物 |
TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
WO2010072155A1 (zh) * | 2008-12-26 | 2010-07-01 | 复旦大学 | 一种嘧啶类衍生物及其制备方法和用途 |
JP5815411B2 (ja) | 2008-12-30 | 2015-11-17 | ライジェル ファーマシューティカルズ, インコーポレイテッド | ピリミジンジアミンキナーゼ阻害剤 |
US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
JP5497152B2 (ja) * | 2009-04-24 | 2014-05-21 | エフ.ホフマン−ラ ロシュ アーゲー | ブルトン型チロシンキナーゼの阻害薬 |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
CA2763099A1 (en) * | 2009-05-22 | 2010-11-25 | Exelixis, Inc. | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases |
KR20120087808A (ko) | 2009-05-26 | 2012-08-07 | 엑셀리시스, 인코포레이티드 | PI3K/m TOR의 억제제로서의 벤즈옥사제핀 및 이의 사용 및 제조 방법 |
TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
ES2642586T3 (es) | 2009-07-27 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de canales iónicos |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
US8729265B2 (en) | 2009-08-14 | 2014-05-20 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
AU2010295690B2 (en) | 2009-09-16 | 2016-07-28 | Celgene Avilomics Research, Inc. | Protein kinase conjugates and inhibitors |
SG181965A1 (en) | 2009-12-30 | 2012-08-30 | Avila Therapeutics Inc | Ligand-directed covalent modification of protein |
JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
PL2576541T3 (pl) | 2010-06-04 | 2016-10-31 | Pochodne aminopirymidyny jako modulatory lrrk2 | |
EA026385B9 (ru) | 2010-07-02 | 2017-08-31 | Джилид Сайэнс, Инк. | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов |
BR112013003388A2 (pt) | 2010-08-10 | 2016-07-12 | Celgene Avilomics Res Inc | sal de besilato de um inibidor de btk |
CA2815858C (en) | 2010-11-01 | 2018-10-16 | Celgene Avilomics Research, Inc. | Heterocyclic compounds and uses thereof |
EP2635285B1 (en) | 2010-11-01 | 2017-05-03 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
WO2012064706A1 (en) | 2010-11-10 | 2012-05-18 | Avila Therapeutics, Inc. | Mutant-selective egfr inhibitors and uses thereof |
PL2638031T3 (pl) | 2010-11-10 | 2018-03-30 | Genentech, Inc. | Pirazolowo-aminopirymidynowe pochodne jako modulatory LRRK2 |
WO2012074951A1 (en) | 2010-11-29 | 2012-06-07 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
US8546443B2 (en) | 2010-12-21 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Benzylic oxindole pyrimidines |
WO2012127032A1 (en) | 2011-03-24 | 2012-09-27 | Chemilia Ab | Novel pyrimidine derivatives |
WO2012151561A1 (en) | 2011-05-04 | 2012-11-08 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
EP3275870B1 (en) | 2011-05-10 | 2020-02-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
CA2853498A1 (en) | 2011-10-28 | 2013-05-02 | Celgene Avilomics Research, Inc. | Methods of treating a bruton's tyrosine kinase disease or disorder |
JP6096219B2 (ja) | 2012-01-13 | 2017-03-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | キナーゼ阻害剤として有用なトリアゾリルまたはトリアジアゾリル置換されたピリジル化合物 |
CN104169275B (zh) | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
CN104159896B (zh) | 2012-01-13 | 2017-05-24 | 百时美施贵宝公司 | 用作激酶抑制剂的杂环取代的吡啶基化合物 |
CA2866857C (en) | 2012-03-15 | 2021-03-09 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
CN104302178B (zh) | 2012-03-15 | 2018-07-13 | 西建卡尔有限责任公司 | 表皮生长因子受体激酶抑制剂的固体形式 |
WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
WO2014060375A2 (en) * | 2012-10-18 | 2014-04-24 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
CN104781251B (zh) | 2012-11-08 | 2016-12-14 | 百时美施贵宝公司 | 可作为激酶调节剂的经双环杂环取代的吡啶基化合物 |
KR20150079963A (ko) | 2012-11-08 | 2015-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물 |
WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
KR20150119012A (ko) | 2013-02-08 | 2015-10-23 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Erk 억제제 및 이의 용도 |
JP6091248B2 (ja) * | 2013-02-22 | 2017-03-08 | キヤノン株式会社 | プリンタ |
CN105263929B (zh) | 2013-03-14 | 2018-08-28 | 诺华股份有限公司 | 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物 |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
UY35935A (es) | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
ES2741785T3 (es) | 2014-08-13 | 2020-02-12 | Celgene Car Llc | Formas y composiciones de un inhibidor de ERK |
ES2783852T3 (es) | 2015-06-24 | 2020-09-18 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
ES2822956T3 (es) | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
UY36748A (es) | 2015-06-24 | 2016-12-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen |
EP3328847B1 (en) | 2015-07-29 | 2019-09-11 | Esteve Pharmaceuticals, S.A. | N-(2-(3-(benzyl(methyl)amino)pyrrolidin-1-yl)ethyl)-n-phenyl)propionamide derivatives and related compounds as dual sigma 1 and mu opioid receptor ligands for the treatment of pain |
TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Cxcr2抑制劑 |
CN106831730B (zh) * | 2017-01-11 | 2019-11-26 | 温州医科大学 | 一种取代的二氨基嘧啶类化合物及其在制备抗恶性肿瘤药物中的用途 |
HUE056493T2 (hu) | 2017-05-11 | 2022-02-28 | Bristol Myers Squibb Co | Tienopiridinek és benzotiofének, amelyek hasznosak IRAK4 inibitorokként |
MA50424A (fr) | 2018-01-08 | 2020-08-26 | Chemocentryx Inc | Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2 |
AU2022206470A1 (en) * | 2021-01-07 | 2023-07-27 | Ontario Institute For Cancer Research (Oicr) | Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
WO2024051717A1 (zh) * | 2022-09-08 | 2024-03-14 | 上海深势唯思科技有限责任公司 | 作为plk1抑制剂的化合物及其制备方法和用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4653487A (en) * | 1986-01-29 | 1987-03-31 | Maale Gerhard E | Intramedullary rod assembly for cement injection system |
DE69933680T2 (de) | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | Pyrimidine verbindungen |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
ES2262642T3 (es) * | 2000-04-05 | 2006-12-01 | Kyphon Inc. | Dispositivo para el tratamiento de huesos fracturados y/o enfermos. |
US6749595B1 (en) * | 2000-06-15 | 2004-06-15 | Kieran P. J. Murphy | Cement delivery needle |
US7144414B2 (en) * | 2000-06-27 | 2006-12-05 | Smith & Nephew, Inc. | Surgical procedures and instruments |
GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
US6595998B2 (en) * | 2001-03-08 | 2003-07-22 | Spinewave, Inc. | Tissue distraction device |
US20020188300A1 (en) * | 2001-06-06 | 2002-12-12 | Arramon Yves P. | Cannula system for hard tissue implant delivery |
US6679890B2 (en) * | 2001-08-28 | 2004-01-20 | Joseph Y. Margulies | Method and apparatus for augmentation of the femoral neck |
US7004945B2 (en) * | 2001-11-01 | 2006-02-28 | Spinewave, Inc. | Devices and methods for the restoration of a spinal disc |
US6582439B1 (en) * | 2001-12-28 | 2003-06-24 | Yacmur Llc | Vertebroplasty system |
JPWO2004043936A1 (ja) * | 2002-11-14 | 2006-03-09 | 協和醗酵工業株式会社 | Plk阻害剤 |
ES2325440T3 (es) | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
PL2287156T3 (pl) * | 2003-08-15 | 2013-11-29 | Novartis Ag | 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego |
US7530993B2 (en) * | 2003-10-23 | 2009-05-12 | Trans1 Inc. | Method of spinal fixation |
US7699852B2 (en) * | 2003-11-19 | 2010-04-20 | Zimmer Spine, Inc. | Fenestrated bone tap and method |
US8197666B2 (en) * | 2003-11-28 | 2012-06-12 | Maria Roiner | Method and apparatus for the manufacture of one or more gases |
EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
US7513901B2 (en) * | 2005-05-19 | 2009-04-07 | Warsaw Orthopedic, Inc. | Graft syringe assembly |
WO2007028120A2 (en) * | 2005-09-01 | 2007-03-08 | Dfine, Inc. | Systems and methods for sensing retrograde flows of bone fill material |
US7901409B2 (en) * | 2006-01-20 | 2011-03-08 | Canaveral Villegas Living Trust | Intramedullar devices and methods to reduce and/or fix damaged bone |
-
2005
- 2005-08-17 US US11/206,703 patent/US7521457B2/en not_active Expired - Fee Related
- 2005-08-18 JP JP2007526463A patent/JP5060294B2/ja not_active Expired - Fee Related
- 2005-08-18 EP EP05777896.1A patent/EP1781640B1/de not_active Not-in-force
- 2005-08-18 HU HUE05777896A patent/HUE025285T2/en unknown
- 2005-08-18 BR BRPI0514371-3A patent/BRPI0514371A/pt active Search and Examination
- 2005-08-18 MX MX2007002055A patent/MX2007002055A/es active IP Right Grant
- 2005-08-18 ES ES05777896.1T patent/ES2532611T3/es active Active
- 2005-08-18 CN CNA2005800359954A patent/CN101044137A/zh active Pending
- 2005-08-18 PL PL05777896T patent/PL1781640T3/pl unknown
- 2005-08-18 RU RU2007109870/04A patent/RU2404979C2/ru not_active IP Right Cessation
- 2005-08-18 CA CA2573371A patent/CA2573371C/en not_active Expired - Fee Related
- 2005-08-18 WO PCT/EP2005/054089 patent/WO2006021544A1/de active Application Filing
- 2005-08-18 DK DK05777896T patent/DK1781640T3/en active
- 2005-08-18 NZ NZ553632A patent/NZ553632A/en not_active IP Right Cessation
- 2005-08-18 KR KR1020077004974A patent/KR101277506B1/ko active IP Right Grant
- 2005-08-18 AU AU2005276500A patent/AU2005276500B2/en not_active Ceased
- 2005-08-19 TW TW094128434A patent/TWI421248B/zh not_active IP Right Cessation
- 2005-08-22 AR ARP050103502A patent/AR051195A1/es not_active Application Discontinuation
-
2007
- 2007-01-03 ZA ZA200700084A patent/ZA200700084B/xx unknown
- 2007-02-19 IL IL181421A patent/IL181421A/en active IP Right Grant
-
2009
- 2009-02-05 US US12/366,075 patent/US20090163465A1/en not_active Abandoned
- 2009-02-05 US US12/366,078 patent/US20090149438A1/en not_active Abandoned
-
2010
- 2010-12-20 US US12/972,976 patent/US20110086842A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1781640A1 (de) | 2007-05-09 |
US7521457B2 (en) | 2009-04-21 |
US20090149438A1 (en) | 2009-06-11 |
HUE025285T2 (en) | 2016-03-29 |
TWI421248B (zh) | 2014-01-01 |
RU2007109870A (ru) | 2008-11-10 |
CN101044137A (zh) | 2007-09-26 |
NZ553632A (en) | 2010-12-24 |
US20060148800A1 (en) | 2006-07-06 |
RU2404979C2 (ru) | 2010-11-27 |
CA2573371C (en) | 2013-02-19 |
US20090163465A1 (en) | 2009-06-25 |
ZA200700084B (en) | 2008-02-27 |
AU2005276500B2 (en) | 2012-05-10 |
JP2008510691A (ja) | 2008-04-10 |
US20110086842A1 (en) | 2011-04-14 |
MX2007002055A (es) | 2007-03-29 |
CA2573371A1 (en) | 2006-03-02 |
KR101277506B1 (ko) | 2013-06-25 |
IL181421A0 (en) | 2007-07-04 |
DK1781640T3 (en) | 2015-04-20 |
BRPI0514371A (pt) | 2008-06-10 |
TW200619218A (en) | 2006-06-16 |
JP5060294B2 (ja) | 2012-10-31 |
AU2005276500A1 (en) | 2006-03-02 |
WO2006021544A1 (de) | 2006-03-02 |
EP1781640B1 (de) | 2015-01-07 |
PL1781640T3 (pl) | 2015-06-30 |
IL181421A (en) | 2015-05-31 |
KR20070048757A (ko) | 2007-05-09 |
ES2532611T3 (es) | 2015-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051195A1 (es) | Piridinas como inhibidores de plk | |
PE20230161A1 (es) | Inhibidores de proteinas kras mutantes | |
AR057712A1 (es) | Dihidropteridinonas en el tratamiento de enfermedades respiratorias | |
AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
AR084366A1 (es) | N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k | |
AR077999A1 (es) | Antagonistas de pirimidin y triazin-hepcidina | |
AR065813A1 (es) | Compuesto composicion farmaceutica y metodos para tratar trastornos relacionados con pi3k y mtor y a cancer y para inhibir mtor y pi3k | |
AR074336A1 (es) | Compuestos de arilo con sustituyentes heterociclicos y su uso | |
AR085304A1 (es) | Imidazo[5,1-f][1,2,4]triazinas para el tratamiento de trastornos neurologicos | |
AR075475A1 (es) | Derivados heterociclicos de piperazina utiles como agentes herbicidas y proceso para combatir el crecimiento de plantas indeseadas. | |
AR076775A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
AR050611A1 (es) | Derivados de dihidripteridinona | |
CO6280485A2 (es) | Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina | |
AR060768A1 (es) | Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos. | |
AR056688A1 (es) | Derivados de la 4- amino - quinazolina su preparacion y su aplicacion en terapeutica | |
AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
AR050610A1 (es) | Derivados de dihidropteridinona | |
AR070127A1 (es) | Pirrolo - pirimidinas y pirrolo -piridinas | |
AR068734A1 (es) | Esteroides con actividad agonista del receptor de glucocorticoides | |
AR074052A1 (es) | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa | |
AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
PE20190337A1 (es) | NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
AR073501A1 (es) | Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa | |
AR076236A1 (es) | Compuestos organicos y sus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |